Recombinant C1q Protein Production via Subunit Segmentation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing the C1q protein are unsatisfactory due to its complex structure and the inability to produce complete, correctly structured protein through recombinant means, leading to reproducibility and biological safety concerns when extracted from human or animal serum.

Innovation Solution

Incorporating a peptide sequence DYKDDDDK at the C-terminal end of the C1qC subunit during recombinant production with C1qA and C1qB subunits in an in vitro cell culture, allowing for the generation of a C1q protein with a structure similar to its native form.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If C1q protein is extracted from human or animal serum, then complete C1q protein can be obtained, but biological safety is compromised due to contamination risks from viruses, prions, or parasites

Engineering Contradiction:
Improvebiological safetyVSAvoidproduction complexity
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The C1q protein is divided into three separate subunits (C1qA, C1qB, C1qC) that are expressed individually in recombinant cell cultures. Each subunit contains specific amino acid sequences that enable their separate production while maintaining the ability to self-assemble into the complete functional protein structure, thereby eliminating contamination risks from serum extraction.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

A peptide sequence with at least 40% glutamic acid and/or aspartic acid residues serves as a mediator to facilitate the correct folding and assembly of recombinant C1q subunits. This peptide intermediary enables the recombinant subunits to form the native-like bouquet structure without requiring serum extraction, ensuring both safety and structural integrity.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If recombinant production of C1q subunits is attempted, then biological safety is improved, but complete and correctly structured C1q protein cannot be produced

Engineering Contradiction:
Improvebiological safetyVSAvoidprotein structure accuracy
Core Design Contradiction:
ReliabilityVSManufacturing precision

Solution Approach 1:

Specific regions of the C1q subunits are engineered with enhanced properties: the C1qC subunit contains a peptide sequence with at least 40% glutamic acid and/or aspartic acid residues that locally facilitates correct folding and assembly. This local quality enhancement ensures that recombinant subunits can self-assemble into the complete native-like structure with proper disulfide bridges and collagen triple helices.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The amino acid composition of the C1qC subunit is modified by incorporating a peptide sequence with at least 40% glutamic acid and/or aspartic acid residues. This parameter change in charge distribution and chemical properties enables the recombinant subunits to achieve correct folding and assembly into the complete C1q structure, overcoming the limitation of previous recombinant approaches.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If C1q protein structure is maintained as native form, then functional activity is preserved, but production complexity increases due to multimeric assembly requirements

Engineering Contradiction:
Improvefunctional activityVSAvoidproduction process complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The recombinant C1q subunits are designed to self-assemble into the complete functional protein structure without requiring complex external assembly procedures. The C1qC subunit's peptide sequence with enhanced glutamic acid and/or aspartic acid content enables spontaneous correct folding and formation of disulfide bridges, allowing the subunits to automatically form the native-like bouquet structure with proper functional activity.

Inventive Principle:
Principle #25Self-service

Data Source

PatentEP2906593B1Method for preparing c1q recombinant protein
Publication Date: 2020.03.11 INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
  • EP2906593B1 patent drawingFigure 1~3
  • EP2906593B1 patent drawingFigure 4~6
  • EP2906593B1 patent drawingFigure 7~8

AI summary

The present invention relates to a method for recombinant production of a C1q protein or a variant of the C1q protein, in which the protein is recovered from an in vitro culture of cells expressing a C1qA subunit or a variant of the C1qA subunit, a C1qB subunit or a variant of the C1qB subunit, and a C1qC subunit or a variant of the C1qC subunit, in which at least one of the subunits or subunit variants also has at the N-terminus or C-terminus a sequence of amino acids of at least six residues, at least 40% of which are glutamic acid and/or aspartic acid residues.